Xuanzhu Biopharmaceutical Co., Ltd. (HKG:2575)
Hong Kong
· Delayed Price · Currency is HKD 24.00
-0.60 (-2.44%)
Apr 29, 2026, 4:08 PM HKT
Xuanzhu Biopharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Net Income | - | -556.43 | -300.56 | -461.58 | -162.45 | Upgrade
|
| Depreciation & Amortization | - | 33.18 | 31.44 | 18.14 | 15.47 | Upgrade
|
| Other Amortization | - | 0.58 | 0.73 | - | - | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 7.57 | -1.02 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | -9.16 | -15.93 | - | - | Upgrade
|
| Stock-Based Compensation | - | 402.9 | 72.27 | - | - | Upgrade
|
| Other Operating Activities | - | 2.14 | 3.45 | 32.01 | -60.66 | Upgrade
|
| Change in Accounts Receivable | - | -0.19 | - | - | - | Upgrade
|
| Change in Inventory | - | 3.35 | -12.87 | - | - | Upgrade
|
| Change in Accounts Payable | - | 29.67 | 29.48 | - | - | Upgrade
|
| Change in Unearned Revenue | - | -3.55 | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | - | -37.16 | 77.07 | - | - | Upgrade
|
| Operating Cash Flow | - | -127.09 | -115.95 | -411.43 | -207.65 | Upgrade
|
| Capital Expenditures | - | -0.51 | -1.74 | -75.99 | -57.26 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | 0.01 | 0.02 | 180.46 | Upgrade
|
| Cash Acquisitions | - | - | - | -131 | - | Upgrade
|
| Sale (Purchase) of Intangibles | - | -73.05 | -144.61 | - | - | Upgrade
|
| Investment in Securities | - | 205.49 | 191.08 | 250.61 | -292.93 | Upgrade
|
| Other Investing Activities | - | - | - | 5.14 | -5 | Upgrade
|
| Investing Cash Flow | - | 131.93 | 44.73 | 48.77 | -174.73 | Upgrade
|
| Long-Term Debt Issued | - | - | - | 200 | - | Upgrade
|
| Long-Term Debt Repaid | - | -5.26 | -7.58 | -200 | -8 | Upgrade
|
| Net Debt Issued (Repaid) | - | -5.26 | -7.58 | - | -8 | Upgrade
|
| Issuance of Common Stock | - | - | - | 866.21 | 925.93 | Upgrade
|
| Common Dividends Paid | - | - | - | -0.45 | -0.19 | Upgrade
|
| Other Financing Activities | - | -7.16 | -2.33 | -8.08 | -3.23 | Upgrade
|
| Financing Cash Flow | - | -12.43 | -9.9 | 857.69 | 914.51 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | -0.05 | -0.1 | -0.01 | 0.02 | Upgrade
|
| Net Cash Flow | - | -7.64 | -81.22 | 495.01 | 532.16 | Upgrade
|
| Free Cash Flow | - | -127.6 | -117.69 | -487.42 | -264.9 | Upgrade
|
| Free Cash Flow Margin | - | -424.00% | -405831.03% | - | - | Upgrade
|
| Free Cash Flow Per Share | - | -0.28 | -0.26 | -1.24 | - | Upgrade
|
| Cash Income Tax Paid | - | 0.01 | 0.01 | 7.87 | 2.97 | Upgrade
|
| Levered Free Cash Flow | - | 20.98 | - | -336.77 | -171.5 | Upgrade
|
| Unlevered Free Cash Flow | - | 21.17 | - | -336.08 | -171.26 | Upgrade
|
| Change in Working Capital | - | -7.87 | 93.68 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.